Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement
- PMID: 31032299
- PMCID: PMC6462602
- DOI: 10.21037/atm.2019.01.50
Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement
Conflict of interest statement
Conflicts of Interest: Neeraj Agarwal reports consultancy to Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono, BMS, Astra Zeneca, Foundation One, Astellas, Ely Lilly, Bayer, Argos, Medivation, Clovis, and Nektar; and research funding to my institution on my behalf from Active Biotech, Astra Zeneca, Bavarian Nordic, BMS, Calithera, Celldex, Eisai, Exelixis, Genentech, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, New link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Sanofi, Takeda, and Tracon. The other authors have no conflicts of interest to declare.
Comment on
-
Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma.Cancer Med. 2018 Nov;7(11):5431-5438. doi: 10.1002/cam4.1790. Epub 2018 Oct 10. Cancer Med. 2018. PMID: 30306741 Free PMC article.
References
-
- Amin MB, Edge SB, Greene FL, et al. editors. AJCC Cancer Staging Manual. 8th ed. Switzerland: Springer, 2017.
-
- Greene FL, Balch CM, Haller DG, et al. editors. AJCC Cancer Staging Manual. 6th ed. New York: Springer, 2002.
-
- Edge SB, Byrd DR, Compton CC, et al. editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer, 2010.
-
- National Comprehensive Cancer Network. NCCN Guidelines Version 2.2019 Kidney Cancer. Available online: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf. Retrieved December 24, 2018.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources